What is CyberAgent's annual revenue?
CyberAgent's annual revenue for the fiscal year ending September 30, 2025, was 874.03 billion JPY, marking a 9.09% year-over-year growth.
Related FAQs
Cytokinetics, Incorporated is a prominent, publicly traded biopharmaceutical enterprise headquartered in South San Francisco, California, focusing on the discovery and development of muscle activators and novel treatments for cardiovascular and neuro...
CyberAgent, Inc. is a major Japanese digital media, advertising, and internet enterprise headquartered in Tokyo.
CyberAgent reported revenue of 874.03 billion JPY for the fiscal year ending September 30, 2025.
As of August 2026, CyberAgent has a market capitalization of approximately $4.66 billion USD.
CyberAgent’s culture emphasizes innovation, "freedom with self-responsibility," talent development, and teamwork.
CyberAgent, a prominent Japanese technology and media firm, generally receives positive marks from employees regarding its company culture and work-life balance.
CyberAgent's mission is "to break through stagnation with new power and the internet," focusing on overcoming stagnation via digital innovation, contributing to the digital transformation of industries, and competing globally by fusing technology wit...
CyberAgent, Inc. is a prominent Japanese digital enterprise operating diverse subsidiaries across internet media, video streaming, and online gaming sectors.
CyberAgent maintains a clear commitment to ethical research and corporate responsibility, aiming to use technology for the advancement of society.
CyberAgent's market capitalization as of August 2026 is approximately $4.66 billion USD.
Yes, CyberAgent is heavily involved in artificial intelligence research and development.
CyberAgent, Inc. is a prominent Japanese digital enterprise operating major business segments spanning media streaming, internet advertising, and mobile video game development.
CyberAgent, a prominent digital media and internet enterprise, offers an exceptional employee benefits ecosystem designed to attract top-tier engineering and creative talent.
Yes, Cytokinetics has received FDA approval for its drug MYQORZO (aficamten). The drug was approved in late 2025 for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.